Article Text

Download PDFPDF
Randomised controlled trial
Duodenal infusion of stool is more effective than vancomycin in patients with recurrent Clostridium difficile
  1. Adam M Berg,
  2. Francis A Farraye
  1. Section of Gastroenterology, Boston Medical Center, Boston, Massachusetts, USA
  1. Correspondence to Dr Francis A Farraye
    Section of Gastroenterology, Boston Medical Center, 85 East Concord St, Suite 7711, Boston, MA 02118, USA; francis.farraye{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Clostridium difficile infection (CDI) is increasing in both inpatients and outpatients. CDI accounted for approximately 336 600 inpatient hospitalisations in the USA in 2009.1 Recurrent CDI (RCDI) occurs in 15–30% of patients after the initial infection and in 40–65% with subsequent infections.1 Guidelines recommend that for mild disease, a first recurrence can be treated with the same initial antibiotic regimen; however, severe recurrent disease should be treated with vancomycin.2 Stool transplant or faecal microbiota transplantation (FMT) has been recommended in a recent gastrointestinal (GI) guideline for RCDI.3


This was the first open-label non-blinded …

View Full Text


  • Competing interests FAF has received research funding from Optimer Pharmaceuticals. He has been on advisory boards for Abbvie, Jansen, Prometheus, Salix, UCB and has been a consultant for Santarus.